GeoMx™ Digital Spatial Profiler Publications

Featured Publications


Balko J, et al.

A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nature Medicine 2019
First application in assessing immune toxicity


Van TM, Blank C

A user's perspective on GeoMxTM digital spatial profiling. Immuno-Oncology Technology 2019
First Beta User experience captured


Rimm D, et al.

High-plex predictive marker discovery for melanoma immunotherapy treated patients using Digital Spatial Profiling. CCR epub 2019
Demonstrates novel strategy for biomarker discovery


Wargo J, et al.

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 2018; 24(11): 1649-54.
First publication on biomarker discovery application


Blank CU, et al.

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med 2018; 24: 1655-1661.
First publication on biomarker discovery application


Ihle C, et al.

Distinct tumor microenvironment of lytic and blastic bone metastases in prostate cancer patients. JITC 2019; 7: 293.
First GeoMx DSP publication Journal for ImmunoTherapy of Cancer


Rozeman EA, Prevoo W, et al.

Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM). Melanoma Res. 2019 Dec. 26; 10.1097.
New GeoMx DSP publication


Farren MR, Sayegh L, et al.

Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemo- and radiotherapy. JCI Insight 2019 Dec 12; 130362: 10.1172.
New GeoMx DSP publication in JCI Insight


Helmink B, Wargo J, et al.

B-cells and tertiary lymphoid structures (TLS) contribute to immune checkpoint blockade response. Nature 2020; 7: 293.
Second GeoMx DSP paper from Wargo group


Cabrita R, Jönsson G, et al.

Tertiary lymphoid structures improve melanoma survival and immunotherapy response. Nature 2020; 7: 293.
New GeoMx DSP publication in Nature